Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 12, 2014, Pages 1899-1904

  Pai, Chien Chun Steven ^a   Hsiao, Hui Hua ^a,b   Sun, Kai ^a,c   Chen, Mingyi ^a   Hagino, Takeshi ^a   Tellez, Joseph ^a   Mall, Christine ^a   Blazar, Bruce R ^d   Monjazeb, Arta ^a   Abedi, Mehrdad ^a   Murphy, William J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c ZHENGZHOU UNIVERSITY   (China)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Anti IL 6 therapy; Bortezomib; Skin acute graft versus host disease

Indexed keywords

BORTEZOMIB; INTERLEUKIN 6; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; NEUTRALIZING ANTIBODY; PYRAZINE DERIVATIVE;

ACUTE GRAFT VERSUS HOST DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; MACROPHAGE ACTIVATION; MORTALITY; MOUSE; NONHUMAN; SKIN PROTECTION; ACUTE DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; BLOOD; CD8+ T LYMPHOCYTE; DISEASE MODEL; GRAFT VS HOST DISEASE; LIVER DISEASES; METABOLISM; PATHOLOGY; SKIN DISEASES;

ACUTE DISEASE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; BORTEZOMIB; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; GRAFT VS HOST DISEASE; INTERLEUKIN-6; LIVER DISEASES; MICE; ORGAN SPECIFICITY; PYRAZINES; SKIN DISEASES;

EID: 84912104023     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.07.022     Document Type: Article

References (33)

1. Shlomchik W.D. Graft-versus-host disease. Nat Rev Immunol 2007, 7:340-352.
2. Das R., Komorowski R., Hessner M.J., et al. Blockade of interleukin-23 signaling results in targeted protection of the colon and allows for separation of graft-versus-host and graft-versus-leukemia responses. Blood 2010, 115:5249-5258.
3. Welniak L.A., Blazar B.R., Murphy W.J. Immunobiology of allogeneic hematopoietic stem cell transplantation. Ann Rev Immunol 2007, 25:139-170.
4. Levine J.E. Implications of TNF-alpha in the pathogenesis and management of GVHD. Int J Hematol 2011, 93:571-577.
5. Blazar B.R., Murphy W.J., Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012, 12:443-458.
6. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010, 22:347-352.
7. Chen X., Das R., Komorowski R., et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 2009, 114:891-900.
8. Tawara I., Koyama M., Liu C., et al. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res 2011, 17:77-88.
9. Le Huu D., Matsushita T., Jin G., et al. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease. JInvest Dermatol 2012, 132:2752-2761.
10. Gergis U., Arnason J., Yantiss R., et al. Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease. JClin Oncol 2010, 28:e602-604.
11. Drobyski W.R., Pasquini M., Kovatovic K., et al. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant 2011, 17:1862-1868.
12. Moreau P., Richardson P.G., Cavo M., et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012, 120:947-959.
13. Tung D., Cheung P.H., Kaur P., et al. Anti-inflammatory and immunomodulatory effects of bortezomib in various invivo models. Pharmacology 2011, 88:100-113.
14. Cullen S.J., Ponnappan S., Ponnappan U. Proteasome inhibition up-regulates inflammatory gene transcription induced by an atypical pathway of NF-kappaB activation. Biochem Pharmacol 2010, 79:706-714.
15. Blanco B., Perez-Simon J.A., Sanchez-Abarca L.I., et al. Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. Haematologica 2009, 94:975-983.
16. Ames E., Hallett W.H., Murphy W.J. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clin Exp Immunol 2009, 155:504-513.
17. Koreth J., Stevenson K.E., Kim H.T., et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. JClin Oncol 2012, 30:3202-3208.
18. Koreth J., Stevenson K.E., Kim H.T., et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 2009, 114:3956-3959.
19. Sun K., Wilkins D.E., Anver M.R., et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood 2005, 106:3293-3299.
20. Sun K., Hsiao H.H., Li M., et al. IFN-gamma receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation. JImmunol 2012, 189:2033-2042.
21. Anderson B.E., McNiff J.M., Matte C., et al. Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease. Blood 2004, 104:1565-1573.
22. Ginhoux F., Collin M.P., Bogunovic M., et al. Blood-derived dermal langerin+ dendritic cells survey the skin in the steady state. JExp Med 2007, 204:3133-3146.
23. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999, 285:412-415.
24. Jones S.A. Directing transition from innate to acquired immunity: defining a role for IL-6. JImmunol 2005, 175:3463-3468.
25. McLoughlin R.M., Jenkins B.J., Grail D., et al. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A 2005, 102:9589-9594.
26. Sun K., Welniak L.A., Panoskaltsis-Mortari A., et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A 2004, 101:8120-8125.
27. Sun K., Li M., Sayers T.J., et al. Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation. Blood 2008, 112:1522-1529.
28. Nishiwaki S., Nakayama T., Murata M., et al. Dexamethasone Palmitate Ameliorates Macrophages-Rich Graft-versus-Host Disease by Inhibiting Macrophage Functions. PloS One 2014, 9:e96252.
29. Fielding C.A., Jones G.W., McLoughlin R.M., et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 2014, 40:40-50.
30. Hurst S.M., Wilkinson T.S., McLoughlin R.M., et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001, 14:705-714.
31. Piper K.P., Horlock C., Curnow S.J., et al. CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation. Blood 2007, 110:3827-3832.
32. Terwey T.H., Kim T.D., Kochman A.A., et al. CCR2 is required for CD8-induced graft-versus-host disease. Blood 2005, 106:3322-3330.
33. Ichiba T., Teshima T., Kuick R., et al. Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays. Blood 2003, 102:763-771.